TLR9 and neoplasm: Though the first mechanism could lead to synergy with anti-PD1 agents due to reduced numbers of immunosuppressive PD-L1/2+ cells in the TME, such as tolerogenic myeloid cells or tumor cells, the second mechanism via TLR9 [11] is equally, if not more likely to work in concert with PD-1 blockade.